[A25-158] Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg) – Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2026
Project no.:
A25-158
Commission:
Commission awarded on 16.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children and adolescents aged 6 to ≤ 17 years with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
- Patients weighing between 20 and 40 kg: added benefit not proven
- Patients weighing at least 40 kg: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-158
| Project no. | Title | Status |
|---|---|---|
| A22-64 | Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V | Commission completed |